GPX2 and cancer: While low levels of GPx3 are associated with a poor prognosis in several cancers, its upregulation in PDAC is linked to reduced ROS levels and increased chemoresistance together with superoxide dismutase (SOD1) and peroxidases (GPx2, thyroperoxidase, and myeloperoxidase) [55] (Figure 1).